GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Capex-to-Operating-Income

Gemina Laboratories (XCNQ:GLAB) Capex-to-Operating-Income : 0.00 (As of Apr. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Gemina Laboratories's Capital Expenditure for the three months ended in Apr. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Apr. 2024 was C$-0.79 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Gemina Laboratories Capex-to-Operating-Income Historical Data

The historical data trend for Gemina Laboratories's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Capex-to-Operating-Income Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Capex-to-Operating-Income
- - - -

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gemina Laboratories's Capex-to-Operating-Income

For the Biotechnology subindustry, Gemina Laboratories's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gemina Laboratories's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Capex-to-Operating-Income falls into.



Gemina Laboratories Capex-to-Operating-Income Calculation

Gemina Laboratories's Capex-to-Operating-Income for the fiscal year that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.041) / -5.198
=N/A

Gemina Laboratories's Capex-to-Operating-Income for the quarter that ended in Apr. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.79
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gemina Laboratories  (XCNQ:GLAB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Gemina Laboratories Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Executives
James Damian Tansey Director

Gemina Laboratories Headlines

No Headlines